June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Author Affiliations & Notes
  • kaline sandrelli amorim ferreira
    Ophthalmology, Federal University of Pernambuco, Recife, Per, Brazil
  • Rodrigo Pessoa Cavalcanti Lira
    Ophthalmology, Federal University of Pernambuco, Recife, Brazil
  • Nelise De paiva Lucena
    Ophthalmology, Federal University of Pernambuco, Recife, Brazil
  • Bruna Marília Alves dos Santos
    Ophthalmology, Federal University of Pernambuco, Recife, Brazil
  • Footnotes
    Commercial Relationships   kaline ferreira, None; Rodrigo Lira, None; Nelise Lucena, None; Bruna dos Santos, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4451. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      kaline sandrelli amorim ferreira, Rodrigo Pessoa Cavalcanti Lira, Nelise De paiva Lucena, Bruna Marília Alves dos Santos; OCULAR DELIVERY OF MOXIFLOXACIN-LOADED LIPOSOMES. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4451.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : The purpose of this study was to study the release profile of moxifloxacin encapsulated in liposomes in the aqueous humor as a controlled release system for intracameral application

Methods : Liposomes containing moxifloxacin (MFLX-Lipo) were obtained using the lipid film hydration method and were characterized by particle size and encapsulation efficiency. Fifteen female rabbits were used for the in vivo profile release study. MFLX-Lipo was injected into the anterior chamber of each animal’s right eye. The rabbits were divided into 5 groups, and a sample of aqueous humor (AH) was collected 2, 4, 8, 24, and 48 hours after MFLX-Lipo administration. Moxifloxacin (MFLX) concentrations in the AH were analyzed using high performance liquid chromatography.

Results : MFLX-Lipo exhibited an average size of 60.5 ± 0.72 nm and a particle size distribution of 0.307. The encapsulation efficiency of MFLX in liposomes was 92.24 ± 0.24%. In the in vivo release study of MFLX-Lipo, the maximum concentration of MFLX was achieved within the first 2 hours after administration (5.27 ± 1.09 mg/mL) and was followed by a decrease in intracameral concentration (0.35 ± 0.05 mg/mL) until the 48-hour mark.

Conclusions : The liposomal formulation obtained exhibits properties that make it suitable for administration via a topical ophthalmic route and offers stability and high encapsulation efficiency. In the in vivo study, MFLX-Lipo exhibited a satisfactory aqueous humor release profile, which suggests that it is an option for the prophylaxis of frequent endophthalmitis pathogens.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.



This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.